ATE384526T1 - N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes - Google Patents
N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetesInfo
- Publication number
- ATE384526T1 ATE384526T1 AT04750170T AT04750170T ATE384526T1 AT E384526 T1 ATE384526 T1 AT E384526T1 AT 04750170 T AT04750170 T AT 04750170T AT 04750170 T AT04750170 T AT 04750170T AT E384526 T1 ATE384526 T1 AT E384526T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- diabetes
- sulphonyl
- thiazol
- carbonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- DNVVEHDIVVGYBV-HNNXBMFYSA-N (2s)-3-phenyl-2-[[2-(1,3-thiazol-2-ylcarbamoyl)phenyl]sulfonylamino]propanoic acid Chemical class C([C@@H](C(=O)O)NS(=O)(=O)C=1C(=CC=CC=1)C(=O)NC=1SC=CN=1)C1=CC=CC=C1 DNVVEHDIVVGYBV-HNNXBMFYSA-N 0.000 title 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 2
- 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46310203P | 2003-04-14 | 2003-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE384526T1 true ATE384526T1 (de) | 2008-02-15 |
Family
ID=33300037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04750170T ATE384526T1 (de) | 2003-04-14 | 2004-04-14 | N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040248937A1 (de) |
| EP (1) | EP1633354B1 (de) |
| JP (1) | JP2006524248A (de) |
| KR (1) | KR20050121732A (de) |
| CN (1) | CN1794989A (de) |
| AT (1) | ATE384526T1 (de) |
| AU (1) | AU2004231106A1 (de) |
| BR (1) | BRPI0409447A (de) |
| CA (1) | CA2522080A1 (de) |
| DE (1) | DE602004011511T2 (de) |
| EA (1) | EA200501607A1 (de) |
| MX (1) | MXPA05010937A (de) |
| NO (1) | NO20054769L (de) |
| WO (1) | WO2004092146A2 (de) |
| ZA (1) | ZA200509123B (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572922B2 (en) | 2003-01-27 | 2009-08-11 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| EA200501710A1 (ru) | 2003-04-30 | 2006-06-30 | ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи | Замещённые карбоновые кислоты |
| TWI349550B (en) * | 2003-12-26 | 2011-10-01 | A thiazole derivative and adenosine a2a receptor antagonist containing the same | |
| SI1756064T1 (sl) * | 2004-06-04 | 2008-12-31 | Merck & Co Inc | Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe |
| AU2005269792B9 (en) | 2004-07-22 | 2008-11-27 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| JP2008518926A (ja) * | 2004-10-28 | 2008-06-05 | ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換フェニルアルカン酸 |
| JP2009502923A (ja) | 2005-07-26 | 2009-01-29 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾールを合成するための方法 |
| DE102006013957A1 (de) * | 2006-03-27 | 2007-10-04 | Bayer Healthcare Aktiengesellschaft | Substituierte N-Benzyl-N-phenylbenzolsulfonamide |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| GB0815782D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815784D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| AU2011346670B2 (en) | 2010-12-23 | 2015-05-07 | Pfizer Inc. | Glucagon receptor modulators |
| WO2012100734A1 (en) * | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| PH12013501557A1 (en) | 2011-02-08 | 2019-06-03 | Pfizer | Glucagon receptor modulator |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP2922847A1 (de) | 2012-11-20 | 2015-09-30 | Vertex Pharmaceuticals Incorporated | Verbindungen als inhibitoren der indolamin-2,3-dioxygenase |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| EP2961746B1 (de) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazolderivate als potente rock1- und rock2-inhibitoren |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
| US20170114049A1 (en) | 2014-04-03 | 2017-04-27 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases |
| CN106458938A (zh) | 2014-04-03 | 2017-02-22 | 拜耳制药股份公司 | 手性2,5‑二取代的环戊烷甲酸衍生物及其用途 |
| MX2018009633A (es) | 2016-02-09 | 2018-12-17 | Inventisbio Inc | Inhibidor de indoleamina-2,3-dioxigenasa (ido). |
| CN106632076B (zh) * | 2016-09-20 | 2019-04-30 | 中国药科大学 | 4,6-二苯基嘧啶类化合物、其制备方法和医药用途 |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| KR102606541B1 (ko) * | 2021-04-23 | 2023-11-29 | 가천대학교 산학협력단 | 바이페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN115337301A (zh) * | 2022-07-22 | 2022-11-15 | 汕头大学医学院第一附属医院 | Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用 |
| CN117105870B (zh) * | 2023-08-07 | 2026-01-06 | 中江县人民医院 | 一种磺胺嘧啶衍生物及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ325939A (en) * | 1996-01-23 | 2000-06-23 | Shionogi & Co | Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives |
| GEP20032998B (en) * | 1996-04-12 | 2003-06-25 | Searle & Co | Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors |
| US6677364B2 (en) * | 1998-04-20 | 2004-01-13 | G.D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| DE69724811T2 (de) * | 1996-07-19 | 2004-04-08 | Tularik, Inc., South San Francisco | Pentafluorobenzensulfonamide und analoge |
| CO5011105A1 (es) * | 1997-12-22 | 2001-02-28 | Novartis Ag | Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion |
| CN1308619A (zh) * | 1998-05-12 | 2001-08-15 | 美国家用产品公司 | (2－酰氨基噻唑－4－基)乙酸衍生物 |
| CN1348442A (zh) * | 1999-02-26 | 2002-05-08 | 默克公司 | 新的磺胺化合物及其应用 |
| EP1214324B1 (de) * | 1999-09-10 | 2006-06-14 | Novo Nordisk A/S | Modulatoren der protein tyrosin phosphatase (ptpases) |
| JP4739632B2 (ja) * | 2000-02-05 | 2011-08-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| AU2001248765A1 (en) * | 2000-04-21 | 2001-11-12 | Shionogi And Co., Ltd. | Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders |
| AU4882101A (en) * | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
| WO2001083461A1 (en) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Thiazole and oxazole derivatives |
| CA2415742A1 (en) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| US6472545B2 (en) * | 2000-08-29 | 2002-10-29 | Abbott Laboratories | Protein tyrosine phosphatase inhibitors |
| EP1331224A4 (de) * | 2000-09-29 | 2004-03-17 | Shionogi & Co | Thiazol- und oxazolderivate |
| JP2002114768A (ja) * | 2000-10-11 | 2002-04-16 | Japan Tobacco Inc | ２−（２，５−ジハロゲン−３，４−ジヒドロキシフェニル）アゾール化合物及びそれを含有してなる医薬組成物 |
| WO2002036602A1 (en) * | 2000-11-02 | 2002-05-10 | Ajinomoto Co., Inc. | Novel pyrazole derivatives and diabetes remedies containing the same |
| EP1366012A4 (de) * | 2001-02-09 | 2005-11-02 | Merck & Co Inc | 2-aryloxy-2-arylalkansäuren gegen diabetes und störungen des fettstoffwechsels |
| DE10150172A1 (de) * | 2001-10-11 | 2003-04-30 | Morphochem Ag | Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren |
| EP1438044A1 (de) * | 2001-10-19 | 2004-07-21 | Transtech Pharma, Inc. | Bis-heteroaryl alkane als therapeutische mittel |
| WO2003035610A1 (en) * | 2001-10-26 | 2003-05-01 | Shionogi & Co., Ltd. | Sulfonamide derivative having mmp inhibitory activity |
| CA2467910A1 (en) * | 2001-11-19 | 2003-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of rho c activity |
| WO2003048140A1 (en) * | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| DE60324104D1 (en) * | 2002-01-30 | 2008-11-27 | Amgen Inc | Arylsulfonamidobenzylverbindungen |
| JP4505327B2 (ja) * | 2002-07-30 | 2010-07-21 | メルク・シャープ・エンド・ドーム・コーポレイション | 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物 |
| CA2495943C (en) * | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
-
2004
- 2004-04-14 AU AU2004231106A patent/AU2004231106A1/en not_active Abandoned
- 2004-04-14 MX MXPA05010937A patent/MXPA05010937A/es unknown
- 2004-04-14 DE DE602004011511T patent/DE602004011511T2/de not_active Expired - Fee Related
- 2004-04-14 EA EA200501607A patent/EA200501607A1/ru unknown
- 2004-04-14 CA CA002522080A patent/CA2522080A1/en not_active Abandoned
- 2004-04-14 CN CNA2004800145768A patent/CN1794989A/zh active Pending
- 2004-04-14 KR KR1020057019661A patent/KR20050121732A/ko not_active Withdrawn
- 2004-04-14 JP JP2006510073A patent/JP2006524248A/ja active Pending
- 2004-04-14 BR BRPI0409447-6A patent/BRPI0409447A/pt not_active IP Right Cessation
- 2004-04-14 WO PCT/US2004/011650 patent/WO2004092146A2/en not_active Ceased
- 2004-04-14 US US10/824,057 patent/US20040248937A1/en not_active Abandoned
- 2004-04-14 AT AT04750170T patent/ATE384526T1/de not_active IP Right Cessation
- 2004-04-14 EP EP04750170A patent/EP1633354B1/de not_active Expired - Lifetime
-
2005
- 2005-10-17 NO NO20054769A patent/NO20054769L/no not_active Application Discontinuation
- 2005-11-11 ZA ZA200509123A patent/ZA200509123B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054769L (no) | 2006-01-03 |
| ZA200509123B (en) | 2007-04-25 |
| EP1633354B1 (de) | 2008-01-23 |
| DE602004011511T2 (de) | 2009-01-29 |
| BRPI0409447A (pt) | 2006-04-18 |
| DE602004011511D1 (de) | 2008-03-13 |
| NO20054769D0 (no) | 2005-10-17 |
| KR20050121732A (ko) | 2005-12-27 |
| WO2004092146A2 (en) | 2004-10-28 |
| US20040248937A1 (en) | 2004-12-09 |
| WO2004092146A3 (en) | 2004-12-29 |
| CA2522080A1 (en) | 2004-10-28 |
| CN1794989A (zh) | 2006-06-28 |
| MXPA05010937A (es) | 2005-11-25 |
| JP2006524248A (ja) | 2006-10-26 |
| AU2004231106A1 (en) | 2004-10-28 |
| EP1633354A2 (de) | 2006-03-15 |
| EA200501607A1 (ru) | 2006-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004011511D1 (de) | N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes | |
| EA200501715A1 (ru) | Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в | |
| EA200501713A1 (ru) | Фенилзамещённые карбоновые кислоты | |
| EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
| ATE372324T1 (de) | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen | |
| MXPA05011539A (es) | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| EA200801711A1 (ru) | Пролекарства возбуждающих аминокислот | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| DE602004002394D1 (de) | (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN | |
| TW200630354A (en) | Substituted amino carboxylic acids | |
| ATE383853T1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| ATE520691T1 (de) | Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen | |
| EA200601687A1 (ru) | Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 | |
| EA200970046A1 (ru) | Аминопроизводные в-гомоандростанов и в-гетероандростанов | |
| TW200631949A (en) | Substituted carboxylic acids | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| ATE523199T1 (de) | Pyridazinverbindungen und verfahren | |
| ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| DE602005027228D1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |